Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993007 | 0.85 | PPARA (0.48) | LTA4HMEN1KMT2AMAPTBACE1 | |
| SCHEMBL5991077 | 0.81 | PKM (0.51) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL27551193 | 0.81 | ALDH1A1 (0.59) | LTA4HMEN1KMT2AMAPTBACE1 | |
| SCHEMBL30024032 | 0.79 | CYP1A2 (0.56) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL5734032 | 0.79 | CYP1A2 (0.56) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL26604899 | 0.79 | MEN1 (0.51) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL5991804 | 0.78 | MEN1 (0.51) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL14572101 | 0.78 | L3MBTL1 (0.53) | MEN1KMT2AMAPTBACE1PKM | |
| SCHEMBL5734037 | 0.78 | CYP4F2 (0.55) | LTA4HMEN1KMT2AMAPTBACE1 | |
| SCHEMBL30954335 | 0.78 | CYP4F2 (0.55) | LTA4HMEN1KMT2AMAPTBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL | 2006-08-03 | — | — | US | disclosed |
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | ANDERSSON KJELL (SE) | 2004-11-18 | — | — | US | disclosed |
| US-6630600-B1 | Intermediate for their manufacture, pharmaceutical preparations containing them and the use of the compounds in clinical conditions associated with insulin resistance. | ASTRAZENECA AB (SE) | 2003-10-07 | — | — | US | disclosed |
| EP-1084102-B1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| CN-1312795-A | Novel 3-arylpropionic acid derivatives and analogs thereof | ASTRA ZENECA AKTIEBOLAG (SE) | 2001-09-12 | — | — | CN | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229949-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | LTA4H 2565/4885MEN1 3620/4885KMT2A 3962/4885 |
| US-20060173204-A1 | New 3-aryl propionic acid derivatives and analogs | GPR119, INSR, IRS1 | LTA4H 2565/4885MEN1 3620/4885KMT2A 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.